[{"id":"6599101d-aea2-4fda-beb6-038d37252237","acronym":"","url":"https://clinicaltrials.gov/study/NCT04440735","created_at":"2023-04-26T18:04:49.712Z","updated_at":"2024-07-02T16:35:11.822Z","phase":"Phase 1/2","brief_title":"A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04440735","lead_sponsor":"Kahr Medical","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • DSP-107"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-02"}]